Investor Relations

Esperion Therapeutics, Inc. is an emerging pharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of hypercholesterolemia and other cardiometabolic risk markers.

Esperion Therapeutics is a publicly traded company (since 2013) and is listed on the NASDAQ Global Select Market under the symbol ESPR.

Esperion Therapeutics (NASDAQ: ESPR) 4:00 PM ET on Jul 29, 2015
Last Price Change Open Day High 52-Week High
62.48
6.53  down   (9.462%) 68.82 70.37 120.96
Volume Previous Close Day Low 52-Week Low
1,798,100 69.01 61.55 14.08

View all »   RSSRecent Releases

Jul 29, 2015
Esperion Therapeutics to Provide Second Quarter Program Updates and Financial Results

Jul 28, 2015
Esperion Therapeutics Announces Positive Top-Line Phase 2 Results for ETC-1002 in Patients With Hypercholesterolemia and Hypertension

View all »Events & Presentations

Jul 30, 2015 at 8:30 AM ET
Esperion Therapeutics, Inc. 2015 Investor Day

Aug 6, 2015 at 4:30 PM ET
Esperion Therapeutics Q2 2015 Conference Call